CHEST Physician
-
TETON trials could herald multimodal approach to IPF
Steven Nathan, MD, said the addition of inhaled treprostinil would offer a novel approach that would allow clinicians to target the disease on two fronts.
-
Data support early prone positioning for patients with COVID-19 on mechanical ventilation
Viren Kaul, MD, FCCP, said a recent observational study adds to the body of literature clarifying the optimal timing of prone positioning in this population.
-
Reexamining treatment for RLS: What do the new AASM guidelines teach us?
The key clinical takeaway from the new guidelines is that dopamine agonists are no longer first-line therapy for RLS, and gabapentinoids should be used as primary therapy for most patients.
-
Incorporating climate-related events into clinical practice
Review six steps a pulmonary clinician can take prior to a climate-related event to prepare for a potential disaster scenario and mitigate patient risk.
-
Respiratory care: A glass half full?
The respiratory therapist workforce has been dwindling at a time when demand has been skyrocketing. But good news is on the horizon.
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
Early treatment with CPAP may reduce dementia risk for patients with OSA
Sreelatha Naik, MD, FCCP, said the apparent benefit of CPAP therapy is not a surprise; however, more studies are needed to determine if treating sleep apnea can truly mitigate the higher risk of dementia.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
-
A sticky road: Mucus pathology in COPD
Targeting mucus pathology could fulfill an unmet therapeutic need in managing patients with COPD and provide a novel approach to addressing the underlying mechanisms contributing to airway obstruction.










